To evaluate the therapeutic potential of gastrodin in non-SOD1-mutated ALS MNs, PBMCs were collected from a sporadic ALS patient (sALS), i.e., without known ALS mutations on SOD1, TARDBP, c9orf72, VAPB, and FUS, and reprogrammed to iPSCs. The gene discussed is FUS; the disease is amyotrophic lateral sclerosis.